- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-HER-2-positive gastric cancer, gastroesophageal junction cancer or oesophageal adenocarcinoma.
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 1536KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 343KB)
Nivolumab – November 2021
Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®
Last updated
18 March 2022